BioMarin to Attend Upcoming Investor Conferences
Citi’s 11th Annual Biotech Conference September 7 in Boston
Robert W. Baird & Co. 2016 Global Healthcare Conference September 8 in New York
Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology September 28 in New York
SAN RAFAEL, Calif., Aug. 31, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that management will participate in the Gene Therapy Panel at Citi’s 11th Annual Biotech Conference on September 7, 2016 at 1:00pm ET in Boston, the Robert W. Baird & Co. 2016 Global Healthcare Conference September 8, 2016 at 9:40am ET in New York and the Leerink Partners Roundtable Series: Rare Disease and Immuno-Oncology on September 28, 2016 at 10:00am ET in New York. To access the live webcasts, please visit the investor section of the BioMarin website, www.biomarin.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.biomarin.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
